Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer

Genes and Cancer

Volumn 3, Issue 5-6, 2012, Pages 436-446

  Hantschel, Oliver ^a  

^a EPFL   (Switzerland)

Author keywords

Bcr Abl; kinase inhibitor; kinase structure; tyrosine kinase

Indexed keywords

ABELSON KINASE; ADAPTOR PROTEIN; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; HYBRID PROTEIN; IMATINIB; NILOTINIB; ONCOPROTEIN; PHOSPHOTYROSINE; PHOSPHOTYROSINE 177; PONATINIB; PROTEIN CRK; PROTEIN NUP214; PROTEIN SH2; PROTEIN SH3; REBASTINIB; STAT5 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MYRISTYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84875515439     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912458584     Document Type: Article

References (113)

1. Van Etten RA.Cycling, stressed-out and nervous: cellular functions of c-Abl.Trends Cell Biol. 1999;9:179-86.
2. Pendergast AM.The Abl family kinases: mechanisms of regulation and signaling.Adv Cancer Res. 2002;85:51-100.
3. Pawson T,Kofler M.Kinome signaling through regulated protein-protein interactions in normal and cancer cells.Curr Opin Cell Biol. 2009;21:147-53.
4. Hantschel O,Superti-Furga G.Regulation of the c-Abl and Bcr-Abl tyrosine kinases.Nat Rev Mol Cell Biol. 2004;5:33-44.
5. Pawson T.Protein modules and signalling networks.Nature. 1995;373:573-80.
6. Musacchio A,Saraste M,Wilmanns M.High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides.Nat Struct Biol. 1994;1:546.
7. Overduin M,Rios CB,Mayer BJ,Baltimore D,Cowburn D.Three-dimensional solution structure of the src homology 2 domain of c-abl.Cell. 1992;70:697-704.
8. Gosser YQ,Zheng J,Overduin M,Mayer BJ,Cowburn D.The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.Structure. 1995;3:1075-86.
9. Pluk H,Dorey K,Superti-Furga G.Autoinhibition of c-Abl.Cell. 2002;108:247-59.
10. Barilá D,Superti-Furga G.An intramolecular SH3-domain interaction regulates c-Abl activity.Nat Genet. 1998;18:280-2.
11. Harrison SC.Variation on an Src-like theme.Cell. 2003;112:737-40.
12. Williams JC,Weijland A,Gonfloni S, et al.The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.J Mol Biol. 1997;274:757-75.
13. Sicheri F,Moarefi I,Kuriyan J.Crystal structure of the Src family tyrosine kinase Hck.Nature. 1997;385:602-9.
14. Xu W,Harrison SC,Eck MJ.Three-dimensional structure of the tyrosine kinase c-Src.Nature. 1997;385:595-601.
15. Mayer BJ,Jackson PK,Van Etten RA,Baltimore D.Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo.Mol Cell Biol. 1992;12:609-18.
16. Muller AJ,Pendergast AM,Parmar K,Havlik MH,Rosenberg N,Witte ON.En bloc substitution of the Src homology region 2 domain activates the transforming potential of the c-Abl protein tyrosine kinase.Proc Natl Acad Sci U S A. 1993;90:3457-61.
17. Roumiantsev S,de Aos IE,Varticovski L,Ilaria RL,Van Etten RA.The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.Blood. 2001;97:4-13.
18. Nagar B,Hantschel O,Young MA, et al.Structural basis for the autoinhibition of c-Abl tyrosine kinase.Cell. 2003;112:859-71.
19. Hantschel O,Nagar B,Guettler S, et al.A myristoyl/phosphotyrosine switch regulates c-Abl.Cell. 2003;112:845-57.
20. Wojcik J,Hantschel O,Grebien F, et al.A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain.Nat Struct Mol Biol. 2010;17:519-27.
21. Resh MD.Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins.Biochim Biophys Acta. 1999;1451:1-16.
22. Hantschel O,Wiesner S,Guttler T, et al.Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.Mol Cell. 2005;19:461-73.
23. Hantschel O.Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.Haematologica. 2012;97:157-9.
24. Dorey K,Engen JR,Kretzschmar J, et al.Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.Oncogene. 2001;20:8075-84.
25. Brasher BB,Van Etten RA.c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines.J Biol Chem. 2000;275:35631-7.
26. Schindler T,Bornmann W,Pellicena P,Miller WT,Clarkson B,Kuriyan J.Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.Science. 2000;289:1938-42.
27. Nagar B,Bornmann WG,Pellicena P, et al.Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).Cancer Res. 2002;62:4236-43.
28. Gorre ME,Mohammed M,Ellwood K, et al.Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.Science. 2001;293:876-80.
29. Levinson NM,Kuchment O,Shen K, et al.A Src-like inactive conformation in the abl tyrosine kinase domain.PLoS Biol. 2006;4:e144.
30. Seeliger MA,Nagar B,Frank F,Cao X,Henderson MN,Kuriyan J.c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.Structure. 2007;15:299-311.
31. Nagar B,Hantschel O,Seeliger M, et al.Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.Mol Cell. 2006;21:787-98.
32. Filippakopoulos P,Kofler M,Hantschel O, et al.Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation.Cell. 2008;134:793-803.
33. Grebien F,Hantschel O,Wojcik J, et al.Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.Cell. 2011;147:306-19.
34. Mayer BJ,Hirai H,Sakai R.Evidence that the SH2 domains promote processive phosphorylation by protein-tyrosine kinases.Curr Biol. 1995;5:296-305.
35. Zhou S,Carraway KL,Eck MJ, et al.Catalytic specificity of protein-tyrosine kinases is critical for selective signalling.Nature. 1995;373:536-9.
36. Ponticelli AS,Whitlock CA,Rosenberg N,Witte ON.In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog.Cell. 1982;29:953-60.
37. Smith KM,Van Etten RA.Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.J Biol Chem. 2001;276:24372-9.
38. Nowell PC,Hungerford DA.Minute chromosome in human chronic granulocytic leukemia.Science. 1960;132:1497.
39. Rowley JD.Chromosomal translocations: revisited yet again.Blood. 2008;112:2183-9.
40. Deininger MW,Goldman JM,Melo JV.The molecular biology of chronic myeloid leukemia.Blood. 2000;96:3343-56.
41. Wong S,Witte ON.The BCR-ABL story: bench to bedside and back.Annu Rev Immunol. 2004;22:247-306.
42. Wada H,Mizutani S,Nishimura J, et al.Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein.Cancer Res. 1995;55:3192-6.
43. Brehme M,Hantschel O,Colinge J, et al.Charting the molecular network of the drug target Bcr-Abl.Proc Natl Acad Sci U S A. 2009;106:7414-9.
44. McWhirter JR,Galasso DL,Wang JY.A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.Mol Cell Biol. 1993;13:7587-95.
45. Zhao X,Ghaffari S,Lodish H,Malashkevich VN,Kim PS.Structure of the Bcr-Abl oncoprotein oligomerization domain.Nat Struct Biol. 2002;7:117-20.
46. Taylor CM,Keating AE.Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.Biochemistry. 2005;44:16246-56.
47. Beissert T,Hundertmark A,Kaburova V, et al.Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.Int J Cancer. 2008;122:2744-52.
48. Mian AA,Oancea C,Zhao Z,Ottmann OG,Ruthardt M.Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.Leukemia. 2009;23:2242-7.
49. Pendergast AM,Quilliam LA,Cripe LD, et al.BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.Cell. 1993;75:175-85.
50. Million RP,Van Etten RA.The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.Blood. 2000;96:664-70.
51. Goss VL,Lee KA,Moritz A, et al.A common phosphotyrosine signature for the Bcr-Abl kinase.Blood. 2006;107:4888-97.
52. Holgado-Madruga M,Emlet DR,Moscatello DK,Godwin AK,Wong AJ.A Grb2-associated docking protein in EGF- and insulin-receptor signalling.Nature. 1996;379:560-4.
53. Gu H,Neel BG.The "Gab" in signal transduction.Trends Cell Biol. 2003;13:122-30.
54. Sattler M,Mohi MG,Pride YB, et al.Critical role for Gab2 in transformation by BCR/ABL.Cancer Cell. 2002;1:479-92.
55. Ren R.Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.Nat Rev Cancer. 2005;5:172-83.
56. Dorsey JF,Cunnick JM,Mane SM,Wu J.Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.Blood. 2002;99:1388-97.
57. Nyga R,Pecquet C,Harir N, et al.Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter.Biochem J. 2005;390:359-66.
58. Harir N,Pecquet C,Kerenyi M, et al.Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias.Blood. 2007;109:1678-86.
59. Ye YB,Lin JY,Chen Q, et al.The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.Biochem Pharmacol. 2008;75:2080-91.
60. McCubrey JA,Steelman LS,Abrams SL, et al.Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.Leukemia. 2008;22:708-22.
61. Perrotti D,Jamieson C,Goldman J,Skorski T.Chronic myeloid leukemia: mechanisms of blastic transformation.J Clin Invest. 2010;120:2254-64.
62. Sawyers CL,Callahan W,Witte ON.Dominant negative MYC blocks transformation by ABL oncogenes.Cell. 1992;70:901-10.
63. Nichols GL,Raines MA,Vera JC,Lacomis L,Tempst P,Golde DW.Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.Blood. 1994;84:2912-8.
64. Feller SM.Crk family adaptors-signalling complex formation and biological roles.Oncogene. 2001;20:6348-71.
65. Senechal K,Halpern J,Sawyers CL.The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.J Biol Chem. 1996;271:23255-61.
66. Jankowski W,Saleh T,Pai M-T,Sriram G,Birge RB,Kalodimos CG.Domain organization differences explain Bcr-Abl's preference for CrkL over CrkII.Nat Chem Biol. 2012;8:590-6.
67. Shuai K,Halpern J,ten Hoeve J,Rao X,Sawyers CL.Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.Oncogene. 1996;13:247-54.
68. Nieborowska-Skorska M,Wasik MA,Slupianek A, et al.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.J Exp Med. 1999;189:1229-42.
69. Hoelbl A,Kovacic B,Kerenyi MA, et al.Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.Blood. 2006;107:4898-906.
70. Hoelbl A,Schuster C,Kovacic B, et al.Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.EMBO Mol Med. 2010;2:98-110.
71. Warsch W,Kollmann K,Eckelhart E, et al.High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.Blood. 2011;117:3409-20.
72. Hantschel O,Warsch W,Eckelhart E, et al.BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.Nat Chem Biol. 2012;8:285-93.
73. Nelson EA,Walker SR,Weisberg E, et al.The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.Blood. 2011;117:3421-9.
74. Graux C,Cools J,Melotte C, et al.Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.Nat Genet. 2004;36:1084-9.
75. De Keersmaecker K,Rocnik JL,Bernad R, et al.Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore.Mol Cell. 2008;31:134-42.
76. De Keersmaecker K,Versele M,Cools J,Superti-Furga G,Hantschel O.Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.Leukemia. 2008;22:2208-16.
77. Quintas-Cardama A,Tong W,Manshouri T, et al.Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.Leukemia. 2008;22:1117-24.
78. De Braekeleer E,Douet-Guilbert N,Rowe D, et al.ABL1 fusion genes in hematological malignancies: a review.Eur J Haematol. 2011;86:361-71.
79. Cazzaniga G,Tosi S,Aloisi A, et al.The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts.Blood. 1999;94:4370-3.
80. Million RP,Harakawa N,Roumiantsev S,Varticovski L,Van Etten RA.A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.Mol Cell Biol. 2004;24:4685-95.
81. Druker BJ.Translation of the Philadelphia chromosome into therapy for CML.Blood. 2008;112:4808-17.
82. Mullard A.FDA drug approvals.Nat Rev Drug Discov. 2011 2012;11:91-4.
83. Rix U,Hantschel O,Durnberger G, et al.Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets.Blood. 2007;110:4055-63.
84. Hochhaus A,O'Brien SG,Guilhot F, et al.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia. 2009;23:1054-61.
85. Soverini S,Hochhaus A,Nicolini FE, et al.BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Blood. 2011;118:1208-15.
86. Weisberg E,Manley PW,Breitenstein W, et al.Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Cancer Cell. 2005;7:129-41.
87. Shah NP,Tran C,Lee FY,Chen P,Norris D,Sawyers CL.Overriding imatinib resistance with a novel ABL kinase inhibitor.Science. 2004;305:399-401.
88. Kantarjian H,Jabbour E,Grimley J,Kirkpatrick P.Dasatinib.Nat Rev Drug Discov. 2006;5:717-8.
89. Vajpai N,Strauss A,Fendrich G, et al.Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.J Biol Chem. 2008;283:18292-302.
90. Hantschel O,Rix U,Schmidt U, et al.The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.Proc Natl Acad Sci U S A. 2007;104:13283-8.
91. Hantschel O,Rix U,Superti-Furga G.Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.Leuk Lymphoma. 2008;49:615-9.
92. Saglio G,Kim D-W,Issaragrisil S, et al.Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.N Engl J Med. 2010;362:2251-9.
93. Kantarjian H,Shah NP,Hochhaus A, et al.Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med. 2010;362:2260-70.
94. Quintas-Cardama A,Cortes J.Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Clin Cancer Res. 2008;14:4392-9.
95. O'Hare T,Shakespeare WC,Zhu X, et al.AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.Cancer Cell. 2009;16:401-12.
96. Chan WW,Wise SC,Kaufman MD, et al.Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.Cancer Cell. 2011;19:556-68.
97. Cortes JE,Kim D-W,Pinilla-Ibarz J, et al.Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.Blood. 2011;118:109.
98. Adrian FJ,Ding Q,Sim T, et al.Allosteric inhibitors of Bcr-abl-dependent cell proliferation.Nat Chem Biol. 2006;2:95-102.
99. Zhang J,Adrián FJ,Jahnke W, et al.Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.Nature. 2010;463:501-6.
100. Gallipoli P,Abraham SA,Holyoake TL.Hurdles toward a cure for CML: the CML stem cell.Hematol Oncol Clin North Am. 2011;25:951-66.
101. Carella AM,Goldman JM,Martinelli G,Melo JV,Perrotti D.Chronic myeloid leukemia: the basis of treatment for tomorrow.Haematologica. 2011;96:1737-9.
102. Sloma I,Jiang X,Eaves AC,Eaves CJ.Insights into the stem cells of chronic myeloid leukemia.Leukemia. 2010;24:1823-33.
103. Hu Y,Liu Y,Pelletier S, et al.Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.Nat Genet. 2004;36:453-61.
104. Donato NJ,Wu JY,Stapley J, et al.BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.Blood. 2003;101:690-8.
105. Wu J,Meng F,Kong LY, et al.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.J Natl Cancer Inst. 2008;100:926-39.
106. Warmuth M,Bergmann M,Priess A,Hauslmann K,Emmerich B,Hallek M.The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.J Biol Chem. 1997;272:33260-70.
107. Samanta A,Perazzona B,Chakraborty S, et al.Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.Leukemia. 2011;25:463-72.
108. Traer E,Mackenzie R,Snead J, et al.Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.Leukemia. 2012;26:1140-3.
109. Steen H,Fernandez M,Ghaffari S,Pandey A,Mann M.Phosphotyrosine mapping in Bcr/Abl oncoprotein using phosphotyrosine-specific immonium ion scanning.Mol Cell Proteomics. 2003;2:138-45.
110. Rush J,Moritz A,Lee KA, et al.Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.Nat Biotechnol. 2005;23:94-101.
111. Titz B,Low T,Komisopoulou E,Chen SS,Rubbi L,Graeber TG.The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization.Oncogene. 2010;29:5895-910.
112. Hamilton A,Helgason GV,Schemionek M, et al.Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.Blood. 2012;119:1501-10.
113. Schiffer CA.CML: how low can you go?.Blood. 2010;116:3686-7.